Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

1-2 years≤5 visitsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteInvestigational MedicinesOralCardiologyEndocrinologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Osilodrostat
Osilodrostat is a substance that reduces high cortisol levels in people with Cushing's disease.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Baxdrostat

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier Universitaire De Bordeaux
Hypertension artérielle
Bordeaux, France
Centre Hospitalier Universitaire Amiens Picardie
Service d’endocrinologie
Colomiers, France
Assistance Publique Hopitaux De Paris
Hypertension
Issy-les-Moulineaux, France
Sponsor: AstraZeneca AB
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.